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Introduction {#sec1-1}
============

Traumatic brain injury (TBI) is a leading cause of mortality and morbidity. Following injury, microenvironmental signals released from areas of cell loss can induce neuroblasts to differentiate into oligodendrocyte progenitor cells, resulting in partial recovery of neurological function (Jones and Connor, 2017). However, these endogenous neural stem cells are unable to migrate effectively to areas of injury and to adequately differentiate into functional neurons. There are no efficient therapies for repairing TBI-related loss of cerebral parenchyma. To address this problem, stem/progenitor cells have been transplanted into injured adult brains to replace dead or injured tissues (Pettikiriarachchi et al., 2010). The transplantation of human fetal neural progenitor cells in a clinically adapted model after TBI improved the long-term functional outcome because of increased angiogenesis and reduced astrogliosis (Skardelly et al., 2011). Bone marrow mesenchymal stem cells (BMSCs), pluripotent adult stem-like cells that are capable of differentiating into neuron-like cells, can be easily obtained and rapidly amplified and raise few ethical issues or immunological rejection problems. Multiple hormonal and neurotrophic factors secreted by BMSCs promote the growth, differentiation and protection of endogenous neuronal precursor cells and thus exert positive effects on nerve damage repair and regeneration (Cantinieaux et al., 2013; Xia et al., 2013; Chen et al., 2015; Greer et al., 2017). During cell transplantation therapy for TBI, cell distribution and survival rate play vital roles in the overall recovery of neural functional (Guan et al., 2013). To promote effectively targeted delivery of cells or other therapeutic factors to the brain, biomaterials are being used in combination with cell therapies. This strategy is known as brain tissue engineering (Orive et al., 2009). Therefore, tissue engineering approaches are raising the possibility of enhancing brain repair and regeneration at an injury site to re-establish functionality at both the cellular and organ levels.

Collagen-chitosan scaffolds are widely used in brain tissue engineering because of several favorable features, such as biodegradability, low antigenicity, good biocompatibility, and absence of pyrogenic effects (Ji et al., 2011; Moura et al., 2016; Fu et al., 2017a, b). Guan et al. (2013) loaded human mesenchymal stem cells into collagen scaffolds to treat TBI in rats, which facilitated initial engraftment and supported the survival of grafted cells after transplantation. Lu et al. (2007) implanted collagen scaffolds impregnated with human marrow stromal cells into the cortical lesion cavity of TBI rats, and showed that a stem cell-populated porous material can improve spatial learning and sensorimotor functions. As a natural amino polysaccharide with structural similarity to glycosaminoglycan, chitosan and its derivatives are superior supporting materials for tissue engineering applications because of their excellent biocompatibility, biodegradability and low immunogenicity (Prabaharan and Sivashankari, 2016). Chitosan served as an effective neuroprotector following acute spinal cord trauma (Chedly et al., 2017). Mo et al. (2010) implanted a chitosan scaffold into an injured adult rat hippocampus, which stimulated axons and cells to migrate into the damaged area and to rebuild the neural circuit, with subsequent improvement in the impaired cognitive function. A neuroprotective effect was also seen after collagen-chitosan scaffolds loaded with BMSCs were successfully prepared and transplanted into the ischemic area of an animal ischemic stroke model (Yan et al., 2015).

Previous analysis of collagen or chitosan-based scaffolds for brain tissue engineering applications has mainly focused on cytocompatibility or regional histochemical evaluation (Guan et al., 2013; Yan et al., 2015; Betancur et al., 2017). In this study, to explore an effective treatment method for TBI, collagen-chitosan scaffolds were prepared and impregnated with BMSCs. These were then implanted into a TBI rat model to test biocompatibility, immunogenicity and their ability to promote the regeneration of neurons and to improve functional outcomes.

Materials and Methods {#sec1-2}
=====================

BMSC culture, identification and labeling {#sec2-1}
-----------------------------------------

Six specific-pathogen-free, healthy, 3-week-old male Wistar rats weighing 100 g were provided by the Environment Institute of the Academy of Military Medical Sciences, Chinese People's Liberation Army, China \[license number: SCXK (Jing) 2015-006\]. All rats were used for BMSC isolation. All experimental procedures were approved by the Institutional Animal Investigation Committee of Capital Medical University, China (approval No. AEEI-2015-035) in December 2015 and performed in accordance with the National Institutes of Health (USA) guidelines for care and use of laboratory animals (NIH Publication No. 85-23, revised 1996). We also conformed to internationally accepted ethical standards. All rats were handled humanely and the experimental procedures were in accordance with our institutional guidelines and research ethics. Rats were euthanized by terminal anesthesia and BMSCs from whole bone marrow of all four limbs of each rat were collected and cultured using a complete bone marrow adherent method (Zhao et al., 2011). Flow cytometry was performed to purify passage 3 cells using CD29-FITC (fluorescein isothiocyanate) and CD45RA-PE (phycoerythrin) surface antigen detection. Forty-eight hours prior to cell transplantation, a final concentration of 10 μM of BrdU was added to the culture medium to label BMSCs. All reagents were provided by Sinopharm Chemical Reagent Co., Ltd., Beijing, China and all the chemicals were of analytical grade and were used as received unless otherwise noted. Deionized water was used throughout.

Scaffold preparation, porosity and degradation evaluation {#sec2-2}
---------------------------------------------------------

Collagen-chitosan porous scaffolds were produced using a freeze-drying method (Kim et al., 2007). Briefly, 1 mL of a 2% collagen-chitosan and acetic acid solution was put into a well of a 24-well plate and incubated at 4°C for 6 hours and then at −25°C overnight. The scaffold was then dried in a freeze-drying machine at −75°C for 24 hours. Subsequently, 1 mL 0.1 M NaOH was added to each well, incubated for 20 minutes and the scaffold then dried again with the freeze-drying machine. Finally, the powder (or pellet) was immersed in 75% ethanol for 30 minutes and then rinsed thoroughly five times with phosphate-buffered saline. The following formula was used to measure its porosity: *P* = (V1−V3)/V × 100%; where 'P' is the porosity of the collagen-chitosan porous scaffold; 'V1' is the total volume of ethanol; 'V3' is the remaining ethanol volume after removing the collagen-chitosan porous scaffold; 'V' is the total volume of the scaffold. In a preliminary experiment, we performed a degradation test by immersing the scaffold into phosphate-buffered saline and transplanting it into a rat TBI model.

Scanning electron microscopy {#sec2-3}
----------------------------

The collagen-chitosan porous scaffolds were cut into small pieces, rinsed repeatedly with phosphate-buffered saline, fixed with 2.5% glutaraldehyde and then incubated in 1% of osmium tetroxide (OsO~4~) at 4°C. After gradient ethanol dehydration, scaffold pieces were dried using a critical point drying apparatus, and then coated with the gold ion sputtering method. Samples were observed and photographed using a scanning electron microscope (Hitachi, Tokyo, Japan).

Cell seeding before transplantation {#sec2-4}
-----------------------------------

Collagen-chitosan porous scaffolds with a volume size of 3.0 mm × 3.0 mm × 2.0 mm were prepared by the freeze-drying method (Zhang et al., 2013). After disinfection in alcohol, each scaffold was cultured with BrdU-labeled BMSCs at a cell concentration of 2 × 10^6^/μL at 37°C in a 5% CO~2~, and saturated humidity incubator for 48 hours. The morphology of BMSCs adhered within scaffolds was observed by scanning electron microscopy.

Establishment of a TBI model and treatment with BMSC-impregnated collagen-chitosan scaffolds {#sec2-5}
--------------------------------------------------------------------------------------------

Forty-four, 12-week-old, male, specific-pathogen-free Wistar rats, weighing approximately 250 g were used. Another cohort of animals (*n* = 8) allocated to groups A--D were sacrificed for immunohistochemistry. All rats were obtained from the Environment Institute of the Academy of Military Medical Sciences, Chinese People's Liberation Army, China. The animals were housed (five per cage) with food and water available *ad libitum* and were maintained on a 12-hour light/dark cycle (lights on at 7:00 a.m.) in a controlled temperature (22°C) environment. The above conditions were maintained throughout the experiments.

The rat TBI model was prepared according to the principle of Feeney's free-fall combat injury (Blennow et al., 2012). Rats were intraperitoneally anesthetized with 10% chloral hydrate (0.33 mL/100 g) and then placed in a stereotactic frame. A 10 mm diameter craniotomy was performed adjacent to the sagittal suture, and midway between lambda and bregma. The endocranium was kept intact over the cortex. TBI was induced with the weight drop impact acceleration method using a controlled cortical impact device. A sterile metal plate was used to prevent skull fracture. After pushing the fascia aside, the steel was placed on the dura. The head was then placed in an appropriate position on a platform and a band was put under the lower jaw, which allowed head movement when the impact was created by the falling of a 300 g weight. The weight was dropped from a height of 1 meter onto the parietal bone.

Fifty-two rats were randomly and equally assigned to four groups (*n* = 13): Group A (TBI + immunosuppressor + BMSCs/scaffold), group B (TBI + BMSCs/scaffold), group C (TBI + BMSCs stereotactic injection), and group D (TBI model with scalp incision and skull window). For groups A and B, at 72 hours after TBI the cell/scaffold complexes were transplanted *in situ* into the damaged brain tissue area. Under aseptic conditions and general anesthesia with ketamine (40 mg/kg) and xylazine (8 mg/kg), a 1 cm incision was made along the midline of the scalp. The lesion cavity induced by TBI in the left hemisphere was exposed. A scaffold seeded with BMSCs was placed directly into the lesion cavity without removal of additional brain tissue, and subsequently covered by surgical foam (polyurethane foam). The incision was closed with 4-0 absorbable gut surgical sutures. In group C, the rats received a transplantation of a single stereotactic BMSC injection. Group A rats were given intravenous cyclosporin 12 hours prior to the transplantation and on days 1--5 after the transplantation. Simultaneously, rats of other groups were given intravenous injections of normal saline. The experimental process is illustrated in **[Figure 1](#F1){ref-type="fig"}**.

![Illustration of the treatments given to the rats of four groups.\
BMSCs: Bone marrow mesenchymal stem cells.](NRR-14-1780-g002){#F1}

Behavioral and cognitive function tests {#sec2-6}
---------------------------------------

Modified neurological severity scores (mNSS) were used to assess neurological function of rats before TBI (day 0), and on day 1, 7, 14 and 35 after TBI (Mahmood et al., 2011). Briefly, the mNSS test is scaled from 0 to 18; a score of 0 indicates normal and 18 indicates a maximal deficit (Mahmood et al., 2011).

At 31--35 days after TBI, the Morris water maze test was performed, which comprised a navigation test and a spatial probe test. We recorded the time required for the rat to find the platform from entering the water (escape latency) and frequency to cross the original platform within 120 seconds. This test was used to determine the spatial learning and memory capabilities of each rat over 5 consecutive days.

Hematoxylin-eosin staining and immunohistochemistry {#sec2-7}
---------------------------------------------------

Rats were euthanized by excessive anesthesia and the whole brain was isolated on day 7, 14, 32 or 35 after TBI. Conventional paraffin sections were prepared and standard hematoxylin and eosin staining was performed. Immunohistochemical staining was performed for vascular endothelial growth factor (VEGF). Double immunohistochemistry was performed for 5-bromo-2-deoxyuridine (BrdU)/neuron specific enolase (NSE) and BrdU/glial fibrillary acidic protein (GFAP). For double staining, sections were incubated with sheep anti-BrdU antibody and mouse anti-GFAP antibody (1:200, CST, Shanghai, China) or mouse anti-NSE antibody (1:200), simultaneously, at 4°C overnight. Sections were then washed with phosphate-buffered saline and incubated with horseradish peroxidase-labeled rabbit anti-sheep IgG (1:100; Abcam, Shanghai, China) and sheep anti-mouse IgG. The results were observed under an optical microscope (Chongqing Optical Instrument Factory, Chongqing, China) and recorded.

Statistical analysis {#sec2-8}
--------------------

The data were analyzed using SPSS 13.0 statistical software package (SPSS, Chicago, IL, USA) and are expressed as the mean ± SD. A paired *t*-test and one-way analysis of variance analysis were used for data analysis within and among groups. *P* \< 0.05 was considered statistically significant.

Results {#sec1-3}
=======

Identification and morphology of passage 3 BMSCs {#sec2-9}
------------------------------------------------

Primary BMSCs were isolated from rat limbs and adherently cultured. The colony size was remarkably increased by the fifth day. The cells gradually expanded to a spindle-like, polygonal, irregular shape and eventually formed a visible colony. The proportion of mixed cells remained elevated until passage 3 when BMSCs started to develop a relatively uniform morphology and showed fibrous characteristics. The proportion of mixed cells subsequently diminished thereafter (**[Figure 2A](#F2){ref-type="fig"}**). Passage 3 BMSCs were detected by flow cytometry with a CD29-positive rate of 99.97%, and a CD45-positive rate as low as 0.81%. This was taken into consideration to meet with the requirements for cell transplantation (**[Figure 2B](#F2){ref-type="fig"}**).

![Morphology and identification of passage 3 BMSCs.\
(A) Morphology of passage 3 BMSCs (light microscopy, original magnification, 40×). (B) Flow cytometry identification of surface antigen CD29 (99.97%) and CD45 (0.81%) on passage 3 BMSCs. BMSCs: Bone marrow mesenchymal stem cells.](NRR-14-1780-g003){#F2}

Compatibility of BMSCs with the collagen-chitosan porous scaffold in three-dimensional co-culture {#sec2-10}
-------------------------------------------------------------------------------------------------

The porosity of the collagen-chitosan scaffold was measured by the ethanol alteration method, which revealed 90% porosity. The scaffold gradually degraded within 1 month in degradation tests *in vitro* and *in vivo*, which provided the necessary microenvironment for BMSCs to grow and migrate (**[Figure 3](#F3){ref-type="fig"}**). Scanning electron microscopy revealed relatively uniformly sized pores in scaffold cross sections, and the holes were well interconnected. The pore size was estimated at 80--200 μm, with an average size of 140 μm, which matched the size of BMSCs. Scanning electron microscopy showed that BMSCs and porous collagen-chitosan scaffolds were successfully co-cultured *in vitro* for 48 hours. Thereafter, BMSCs spread out on the surface and within the holes of the scaffold. BMSCs in spindle form secreted an extracellular matrix to adhere to the scaffold and they extended their pseudopodia into the material, indicating good cytocompatibility of the scaffold (**[Figure 4](#F4){ref-type="fig"}**). BMSCs therefore grew well in the three-dimensional culture conditions.

![Tissue compatibility of collagen-chitosan scaffolds.\
(A) General shape of collagen-chitosan porous scaffolds. (B) After 1 month, the scaffold was immersed in phosphate-buffered saline, degraded *in vitro* and the porous structure was visible under a microscope. (C) The scaffold was transplanted into a rat brain after traumatic brain injury. The scaffold was fused with brain tissue, but there was still a general structure.](NRR-14-1780-g004){#F3}

![Scanning electron microscopy images of collagen-chitosan porous scaffold impregnated with bone marrow mesenchymal stem cells after co-culture for 48 hours.\
Bone marrow mesenchymal stem cells are indicated by arrows. Original magnification, 300× (A), 5000× (B).](NRR-14-1780-g005){#F4}

Neurological function of TBI rats after transplantation of BMSC-impregnated collagen-chitosan porous scaffold {#sec2-11}
-------------------------------------------------------------------------------------------------------------

### mNSS results {#sec3-1}

There were no significant changes in mNSS for rats in groups A, B, C and D on days 1 and 7 (*P* \> 0.05). In comparison with the model control group (group D), the mNSS of rats in the experimental groups was significantly declined on day 14. There were no significant differences in mNSS scores between group A and group B (*P* \> 0.05), but when all groups were considered, groups C and D exhibited significant differences (*P* \< 0.05). mNSS scores were significantly different between groups C and D (*P* \< 0.01; **[Figure 5](#F5){ref-type="fig"}**).

![Effect of BMSC-impregnated collagen-chitosan porous scaffold transplantation on neurological function of TBI rats.\
Group A: TBI + immunosuppressor + BMSCs/scaffold; group B: TBI + BMSCs/scaffold; group C: TBI + BMSCs stereotactic injection; group D: TBI only. Data are expressed as the mean ± SD (*n* = 10 rats in each group at each time point). \**P* \< 0.05, *vs*. group A/B; \#*P* \< 0.01, *vs*. group C (paired *t*-test and one-way analysis of variance). TBI: Traumatic brain injury; BMSCs: bone marrow mesenchymal stem cells.](NRR-14-1780-g006){#F5}

### Morris water maze test results {#sec3-2}

The average latency to escape in groups A and B was less than that in groups C and D (*P* \> 0.05), while that of group C was less than that of group D (*P* \> 0.05). Moreover, no significant differences were found between groups A and B (**[Figure 6A](#F6){ref-type="fig"}**).

![Morris water maze test of TBI rats transplanted with BMSC-impregnated collagen-chitosan porous scaffold.\
(A) Average frequency of crossing the platform; (B) average escape latency. Group A: TBI + immunosuppressor + BMSCs/scaffold; group B: TBI + BMSCs/scaffold; group C: TBI + BMSCs stereotactic injection; group D: TBI only. Data are expressed as the mean ± SD (*n* = 10 rats in each group at each time point). \**P* \< 0.05, *vs*. group A/B; \#\#*P* \< 0.01, *vs*. group C (paired *t*-test and one-way analysis of variance). TBI: Traumatic brain injury; BMSCs: bone marrow mesenchymal stem cells.](NRR-14-1780-g007){#F6}

Compared with group D (the control model group), the average escape latencies of rats in the other groups were rapidly reduced from day 31 to day 33 after TBI, and slowly reduced from day 34 to day 35. The average escape latency was equivalent between groups A and B (*P* \> 0.05; **[Figure 6](#F6){ref-type="fig"}**). The average escape latency was significantly different between groups C and D (*P* \< 0.05). The average frequency of crossing the platform was not significantly different between groups A and B (*P* = 0.139), but was significantly different between groups C and D (*P* \< 0.01; **[Figure 6B](#F6){ref-type="fig"}**).

Morphology and markers in TBI rat brains after transplantation of BMSC-impregnated collagen-chitosan porous scaffold {#sec2-12}
--------------------------------------------------------------------------------------------------------------------

### Hematoxylin-eosin staining {#sec3-3}

Routine hematoxylin-eosin staining was used to observe the brain tissues of each group. More degenerative cells were observed in the hippocampus, cortex and striatum on the lesion side, which looked like "shrunken pink cells" and "black contracted cells", in group D compared with groups A, B and C. Degenerated cells became more numerous with time in all groups (**[Figure 7](#F7){ref-type="fig"}**).

![Histochemical analysis of the hippocampus of TBI rats transplanted with BMSC-impregnated collagen-chitosan porous scaffold.\
(A, B) HE staining in the hippocampus on the lesion side of TBI rats at 32 days (group A) (A) and 35 days (group B) (B) after BMSC transplantation. The degeneration of cells (arrow) was decreased remarkably with time. (C) Positive VEGF staining (arrow) in the hippocampus of TBI rats 7 days after BMSC transplantation (group A). (D) No VEGF staining was found in the hippocampus of group D. (E) BrdU/NSE double staining (arrow) in the damaged area 7 days after BMSC transplantation (group C). (F) BrdU/NSE double staining (arrow) in the damaged area 14 days after BMSC transplantation (group C). (G) BrdU/GFAP double staining (arrow) in the damaged area 7 days after BMSC transplantation (group A). (H) BrdU/GFAP double staining (arrow) in the damaged area 14 days after BMSC transplantation (group B). Group A: TBI + immunosuppressor + BMSCs/scaffold; group B: TBI + BMSCs/scaffold; group C: TBI + BMSCs stereotactic injection; group D: TBI only. TBI: Traumatic brain injury; BMSCs: bone marrow mesenchymal stem cells; HE: hematoxylin-eosin; VEGF: vascular endothelial growth factor; NSE: neuron specific enolase; GFAP: glial fibrillary acidic protein. Original magnifications: 100× in A--D, 40× in E and G, and 200× in F and H.](NRR-14-1780-g008){#F7}

### VEGF immunopositivity {#sec3-4}

As shown in **[Figure 7](#F7){ref-type="fig"}**, there was significantly greater VEGF staining at the ischemic transplantation area and its surroundings (hippocampal dentate gyrus and subventricular zone) in groups A and B than in group C. No VEGF staining was seen in the above mentioned areas in group D.

### Co-immunopositivity of BrdU/NSE and BrdU/GFAP {#sec3-5}

The double immunohistochemical staining on day 32 after transplantation showed that the growth and differentiation of the BrdU-labeled BMSCs in the brain occurred at different times following transplantation (**[Figure 7](#F7){ref-type="fig"}**). BrdU-positive BMSCs were numerous in the damage area, and eventually also numerous in the periphery of the damaged area after transplantation. Some of the differentiated neuron-like cells had already migrated to a maximum distance of 2 mm along the periphery of the infracted area and even into normal brain tissues. They appeared circular and accumulating. NSE and GFAP were not expressed in BrdU-labeled BMSCs in the cortex and striatum after a short period following transplantation. On day 7, a few GFAP-positive and no NSE-positive BrdU-labeled BMSCs were observed; on day 14, more GFAP-positive and a few NSE-positive BrdU-labeled BMSCs were seen.

Discussion {#sec1-4}
==========

In this study, transplantation therapy was conducted 72 hours after TBI with the purpose of reducing cell damage from cytokines or toxins, such as oxygen free radicals and inflammatory cytokines, which are produced within 24 hours of the injury. Another reason for doing this therapy 24 hours after TBI is that the damaged area was more clearly defined at this time, allowing a better traumatic repair (Blennow et al., 2012). The feasibility of brain tissue engineering using BMSCs seeded in a collagen-chitosan scaffold was verified by this study. When transplanted into the brain, the scaffold provided a viable microstructure for BMSC proliferation and differentiation. Scanning electron microscopy, hematoxylin-eosin staining and immunohistochemical staining indicated that the cell/scaffold transplantation complex and the normal brain tissue around the damaged region integrated well (Maclean et al., 2018).

The use of an immunosuppressive agent (cyclosporin injection) before or after transplantation produced no differences between groups A and B. These results indicate that the BMSC-impregnated collagen-chitosan scaffold showed low immunogenicity and good biocompatibility, which did not invoke the host's immune response. Cyclosporin had no therapeutic effect on group A or B; however, cyclosporin has been investigated as a possible neuroprotective agent for the treatment of TBI with promising results in animal experiments. Cyclosporin blocks the formation of the mitochondrial permeability transition pore, which causes much of the damage associated with head injury and neurodegenerative diseases (Kilbaugh et al., 2011). The application of cyclosporin should be investigated for its potential selective neuroprotective effects, but currently its dose-dependency characteristics remain unknown. Recent studies indicate that gap junction-associated connexin 43 plays an important role in cell cycle regulation and in the function of neural stem/progenitor cells following TBI (Greer et al., 2017).

After transplanting the cell/scaffold complex into the injured cerebral cortex, hematoxylin-eosin staining and double immunohistochemical staining indicated that the seeded BMSCs in the transplantation zone had extended into the brain tissue of the host by day 35. BMSCs survived and eventually differentiated into neurons or glial cells, even though the collagen-chitosan scaffold had partially degraded at the transplantation zone. In group C, relatively few BMSCs could be injected intracranially, and the lesion core rapidly changed into a cavity that lacks a structural substrate to adequately support the inoculated cells. Compared with group D (the control TBI model), neuronal necrosis in the damaged region was dramatically decreased in the complex transplantation groups (group A or B), while number of strongly positive NSE and GFAP and VEGF cells was elevated. TBI causes neurological function deficits leading to cognitive impairment and learning dysfunction; therefore, we examined spatial learning and memory abilities of the test rats using the Morris water maze test and mNSS. The results illustrated that after TBI, mNSS scores gradually decreased in each group. A remarkable effect was detected in the BMSC intracranial injection groups compared with controls. Compared with the pure BMSCs intracranial injection groups and the control model group, neurological deficits and cognitive impairment were improved when the cell/scaffold complex was introduced.

By exploiting a brain tissue engineering technique, three-dimensionally cultured BMSCs accelerated the functional recovery of rats after TBI (Xu et al., 2018). The possible mechanisms of neuroprotection and cognition improvement are that (1) BMSCs can differentiate into neurons and glial cells under specific conditions with vigorous regenerative behaviors. In response to brain damage, BMSCs partially reconstruct the damaged local brain circuits and compensate for the damaged brain cells. (2) BMSCs can alleviate secondary neurological damage after TBI by secreting BDNF, which promotes the restoration of neurological function and improves the local microenvironment following brain damage. (3) Following TBI, BMSCs can stimulate macrophage and endogenous anti-inflammatory cytokine production, which play cardinal roles in immune regulation and promote homeostasis. (4) The collagen-chitosan scaffold forms an effective and delicate substrate for synaptic connections between the transplantation complex and the other neurons of the central nervous system.

As a pilot study, this research has successfully verified the effectiveness of a chitosan-collagen scaffold and BMSCs for brain repair by examining actual therapeutic effects, such as the recovery of neurological, behavioral and cognitive functions. The occurrence of an inflammatory response (Maclean et al., 2018) and cerebral edema following TBI are important factors that contribute to the evolution of brain injury following initial trauma (Winkler et al., 2016).

This study has several limitations. This research was based on rats; therefore, further study is needed before our conclusions can be extended to humans. Moreover, further research should be carried out to control degeneration of the scaffold, as well as to explore related factors and the mechanism by which proliferation, migration, and differentiation occur. We will conduct comprehensive evaluations using a neural conduction pathway tracing method to unveil the underlying mechanisms for neural protection and regeneration.
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